Login to Your Account



Contravir tests ability of FV-100 to turn down shingles pain

By Michael Fitzhugh
Staff Writer

Monday, August 3, 2015

Contravir Pharmaceuticals Inc. has enrolled the first patient in what could be the sole pivotal trial of FV-100, an oral herpes zoster therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription